CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, March 21, 2023, at 11:00 AM PST and Tuesday, March 28, 2023 at 10:00 AM EST. NeuroSense Therapeutics Ltd. welcomes stakeholders, investors, and other individual followers to register and attend these live events.
The presentations will feature Alon Ben-Noon, Chief Executive Officer, and Nedira Salzman-Frenkel, VP of Business Development. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in either of these events will need to register using the links below. As a reminder, registration for the live events may be limited but access to the replay after the events will be on The Company's Investor website.
REGISTER HERE:
Tuesday, March 21, 2023: https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-nrsn-2023-03-21-110000
Tuesday, March 28, 2023: https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-nrsn-2023-03-28-100000
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
About Renmark Financial Communications Inc.
Founded in 1999, Renmark Financial Communications Inc. is North America's leading retail investor relations firm. Employing a strategic and comprehensive mix of exposure tactics; Renmark hosts Virtual Non-Deal Roadshows as well as in-person corporate presentations and maintains daily communications with thousands of brokers and money managers across Canada and the United States. Renmark empowers its publicly-traded clientele to maximize their visibility within the financial community and strengthen their investor audience.
| Last Trade: | US$1.36 |
| Daily Change: | 0.08 6.25 |
| Daily Volume: | 1,299,366 |
| Market Cap: | US$31.460M |
December 18, 2024 December 11, 2024 December 04, 2024 December 02, 2024 October 28, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
